Ventripoint Welcomes Matt Dobson as Marketing Director to Guide Market Development and Product Management
Ventripoint Welcomes Matt Dobson as Marketing Director to Guide Market Development and Product Management
(TheNewswire)
Toronto, Ontario –
ThedNewswire –
June 13, 2024 –
Ventripoint Diagnostics Ltd.
(“Ventripoint”
or the
“Company”),
(TSXV:VPT
)
;
(
OTC:VPTDF)
is
delighted to welcome Matt Dobson as the company’s new Marketing
Director, to accelerate the company’s path to commercialization.
A seasoned professional in strategic marketing, Matt brings a wealth
of experience from his tenure in various marketing roles and
industries, including medical technology, diagnostics, therapeutics,
technology and fast-paced consumer goods.
Based in the U.K., Matt will focus on developing actionable product
development, marketing and sales programs built upon proprietary
market, customer and user insights and ensuring optimal
product-customer fit.
“Matt has excelled in past assignments and will be key in evolving
Ventripoint to becoming a market driven organization,” said
Ventripoint’s CEO Hugh MacNaught. “Our focus is developing
actionable insights on how to drive adoption of Ventripoint’s
technology in routine clinical practice”.
Added Dobson: “Ventripoint’s proposition is unique, offering a
revolutionary mix of accuracy, efficiency, and user-friendliness in
cardiac imaging using artificial intelligence. This affordable tool
promises to advance heart health management, making heart scans with
cMRI levels of accuracy available to more people, at a fraction of the
cost and with results in minutes.”
Dobson’s role begins immediately. His full bio is here (
)
For further information, please
contact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this news release.
About Ventripoint Diagnostics
Ltd.
Ventripoint has become an industry leader in the application of AI
(Artificial Intelligence) to echocardiography. Ventripoint’s VMS
products are powered by its proprietary KBR technology, which is the
result of a decade of development and provides accurate volumetric
cardiac measurements equivalent to MRI. This affordable, gold-standard
alternative allows cardiologists greater confidence in the management
of their patients. Providing better care to patients serves as a
springboard and basic standard for all Ventripoint’s products that
guide our future developments. In addition, VMS+ is versatile and can
be used with all ultrasound systems from any vendor supported by
regulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. The use of any of the words “expect”,
“anticipate”, “continue”, “estimate”,
“objective”, “ongoing”, “may”,
“will”, “project”, “should”,
“believe”, “plans”, “intends” and similar
expressions are intended to identify forward-looking information or
statements. The forward-looking statements and information are based
on certain key expectations and assumptions made by the Company.
Although the Company believes that the expectations and assumptions on
which such forward-looking statements and information are based are
reasonable, undue reliance should not be placed on the forward-looking
statements and information because the Company can give no assurance
that they will prove to be correct.
Since forward-looking statements and information address future events
and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those
currently anticipated due to several factors and risks. Factors which
could materially affect such forward-looking information are described
in the risk factors in the Company’s most recent annual management’s
discussion and analysis that is available on the Company’s profile on
SEDAR at
www.sedar.com.
Readers are cautioned that the
foregoing list of factors is not exhaustive. The forward-looking
statements included in this news release are expressly qualified by
this cautionary statement. The forward-looking statements and
information contained in this news release are made as of the date
hereof and the Company undertakes no obligation to update publicly or
revise any forward-looking statements or information, whether because
of new information, future events or otherwise, unless so required by
applicable securities laws.
Copyright (c) 2024 TheNewswire – All rights reserved.
